Adamax: What's Actually Known About the Semax Analog

Adamax: A Synthetic Analog of Semax

Adamax is a synthetic peptide sold in the research market as a modified version of Semax. Before summarizing what is known, one point deserves emphasis for accuracy: despite the brand name, the verified molecular formula of Adamax contains no adamantane group. The name is market shorthand, not a literal description of the chemistry. This article is transparent about a second, more important limitation — Adamax itself has very little independent peer-reviewed literature, so most of the science below describes its parent scaffold, Semax.

What Adamax Actually Is

Adamax is a Semax analog with a longer peptide chain. Its identity was confirmed by LC-MS at 984 Da, which matches the molecular formula on its certificate of analysis — the formula and the measured mass agree with each other. What it does not have is a public registry entry of its own: no CAS number and no PubChem record. That is unremarkable for an analog that has never been separately registered, and it is why the molecular data below is quoted from the certificate rather than from a chemical database. Adamax is the Semax core with two modifications:

An N-terminal acetyl group capping the start of the peptide
A C-terminal Ala-Gly extension added to the end

That gives the sequence Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly (Ac-MEHFPGPAG). The non-amidated (free-acid) form listed here has a molecular formula of C₄₄H₆₁N₁₁O₁₃S and a molecular weight of 984.11 Da. Semax itself (Met-Glu-His-Phe-Pro-Gly-Pro) is an analog of the ACTH(4-7) fragment with an added Pro-Gly-Pro tail, so Adamax is best described as an analog of an analog.

Why the terminal modifications matter: N-terminal acetylation and C-terminal changes are standard medicinal-chemistry strategies for altering a peptide's resistance to enzymatic breakdown. They are the kind of modification generally intended to influence stability — though, for Adamax specifically, that rationale has not been tested in published studies.

The Semax Scaffold It Is Built On

Because Adamax derives directly from Semax, the meaningful research context is the Semax literature. Semax has been studied primarily as a neuromodulatory peptide, and two directions recur in that work:

Neurotrophic signaling: studies of the Semax scaffold have reported rapid increases in brain-derived neurotrophic factor (BDNF) and related trophic signaling in rodent brain.
Ischemia and gene expression: genome-wide analyses in rat models have described Semax-associated modulation of vascular- and immune-related gene expression under ischemic conditions.

Our Semax research profile covers this parent-scaffold literature in more detail.

A Straight Note on the Evidence

Adamax is a newer designer analog. We could not identify peer-reviewed clinical literature specific to Adamax itself, and it has no registry entry of its own — no assigned CAS number and no PubChem record. Its profile here rests on (1) the molecular identity confirmed on its certificate of analysis and (2) the published research on its parent compound, Semax. The Semax findings should not be assumed to transfer to Adamax without direct study.

Molecular Reference & Research Status

Property	Value
Sequence	Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly (Ac-MEHFPGPAG)
Parent compound	Semax (Met-Glu-His-Phe-Pro-Gly-Pro)
Form	Non-amidated (free acid)
Molecular formula	C₄₄H₆₁N₁₁O₁₃S
Molecular weight	984.11 Da
CAS number	Not assigned

This compound is a research-grade material for in vitro and preclinical laboratory use only. The information above is provided for identification and scientific context and does not constitute medical, clinical, or dosage guidance.

For research purposes only. Not intended for human consumption. This content covers published preclinical research and does not constitute medical, clinical, or dosage guidance.